First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The lab will facilitate the development of herbal and natural-based solutions
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Subscribe To Our Newsletter & Stay Updated
